Valuation : Incyte Corporation

Market Cap 25.22B 21.68B 20.4B 18.61B 34.74B 2,391B 34.92B 242B 93.5B 1,222B 94.69B 92.62B 3,888B P/E 2026 *
55.5x
P/E 2027 * 17.2x
Enterprise Value 20.99B 18.04B 16.98B 15.49B 28.91B 1,990B 29.06B 201B 77.82B 1,017B 78.8B 77.08B 3,236B EV / Sales 2026 *
3.53x
EV / Sales 2027 * 3.07x
Free-Float
98.16%
Yield 2026 *
-
Yield 2027 * -
1 day-1.11%
1 week-0.56%
Current month-0.14%
1 month+2.26%
3 months+22.04%
6 months+29.73%
Current year+26.61%
1 week 106.25
Extreme 106.25
110.15
1 month 103.3
Extreme 103.3
110.75
Current year 77.6
Extreme 77.6
115.4
1 year 69.58
Extreme 69.58
115.4
3 years 47.11
Extreme 47.11
115.4
5 years 47.11
Extreme 47.11
115.4
10 years 47.11
Extreme 47.11
144.13
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Change 5-day change 1-year change 3-year change Capi.($)
-1.13%-0.56% - - 25.22B
-0.91%-5.45%+44.75%-3.35% 80.91B
-0.78%-1.52%-18.45%-36.25% 60.46B
-0.94%-8.21%+465.71%+30.84% 56.02B
-1.77%-5.26%-9.16%+29.36% 49.63B
-0.87%-6.94%-1.87%+148.97% 45.88B
-0.37%-4.59%+47.95%-17.95% 31.4B
+0.22%-2.81%+46.27%+94.40% 25.22B
-2.00%-3.54%-2.68%+156.40% 22.25B
-2.39%-1.54%+61.97%+101.98% 16.59B
Average -1.08%-1.55%+70.50%+56.04% 43.15B
Weighted average by Cap. -1.00%-1.44%+81.62%+37.45%

Financials

2026 *2027 *
Net sales 5.94B 5.11B 4.81B 4.39B 8.19B 563B 8.23B 56.95B 22.03B 288B 22.31B 21.83B 916B 6.27B 5.39B 5.07B 4.62B 8.63B 594B 8.68B 60.04B 23.23B 304B 23.53B 23.01B 966B
Net income 466M 401M 377M 344M 642M 44.16B 645M 4.46B 1.73B 22.57B 1.75B 1.71B 71.83B 1.5B 1.29B 1.21B 1.1B 2.06B 142B 2.07B 14.34B 5.55B 72.48B 5.62B 5.49B 231B
Net Debt -4.23B -3.64B -3.42B -3.12B -5.83B -401B -5.86B -40.54B -15.68B -205B -15.88B -15.54B -652B -5.99B -5.15B -4.85B -4.42B -8.25B -568B -8.3B -57.42B -22.21B -290B -22.5B -22.01B -924B
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
09/09/26 106.25 -1.80% 0
08/09/26 €108.20 -1.46% 0
07/09/26 €109.80 +0.32% 0
04/09/26 €109.45 -0.41% 0
03/09/26 €109.90 +2.85% 25
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
124.40USD
Average target price
127.74USD
Spread / Average Target
+2.68%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!